Optimizing Pain Self-Management in Total Knee Arthroplasty

Sponsor
University of Virginia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06038240
Collaborator
(none)
150
1
2
48
3.1

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the efficacy of a positive affect enhancing intervention designed to reduce pain and augment reward system function in knee osteoarthritis (KOA) patients undergoing total knee arthroplasty (TKA). The scientific premise is that patient use of a positive emotion generative practice - savoring meditation, which has been demonstrated to reduce pain in experimental laboratory settings, enhanced with a pain neuroscience education component about reward system dysfunction as a chronic pain mechanism - is optimally suited to reduce postsurgical pain and augment reward system functioning relative to a Pain Self-Management and Education (PSME) condition. We will randomize 150 patients with KOA undergoing unilateral TKA to a brief, 4-session (20-30 minutes each) course of Savoring Meditation (SM; n = 75) or PSME (n = 75) delivered remotely by trained interventionists in a one-on-one format. We will assess pain and as well as pain-related risk and protective factors both via questionnaire and via weeklong ecological momentary assessment (EMA) data bursts on the following schedule: baseline, post-surgery, and 3-month follow-up. In addition, participants will attend laboratory testing sessions at baseline and 6-weeks post-surgery, during which affective pain modulation and electroencephalographic (EEG) brain biomarkers associated with pain and affect will be recorded. Participants in SM be encouraged to practice their savoring for 5 minutes/day during the week following surgery, as well as to use it to manage pain flares in a self-directed manner.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Savoring Meditation
  • Behavioral: Pain Self-Management and Education
N/A

Detailed Description

Total knee arthroplasty (TKA) is an increasingly utilized, end-stage, cost-effective treatment for knee osteoarthritis (OA), one of the leading causes of disability worldwide (Felson, 2009) whose hallmark symptoms include pain, stiffness, limited range of motion, and physical mobility limitations (NIAMS, 2019). The mechanisms of pain in OA, like most chronic pain conditions, are complex, multifaceted, and involve both central and peripheral sensitization (Bharde et al., 2021), as well as reward system dysfunction (Wang & Ni, 2022). Despite its overall efficacy, a significant portion of patients with TKA (10-34%) continue to experience painful joints following the procedure (Beswick et al., 2012), while an estimated 20% are dissatisfied with the outcome of their procedure (Bourne et al., 2010; Springer & Sotile, 2020). Further, an estimated 20% experience significant post-operative psychological distress in the months following surgery, which longitudinally predicts poorer functional outcomes (Cremeans-Smith et al., 2011). TKA on average fails to improve pain and function to a level comparable to the general population, or to the level achieved by other joint replacement procedures (i.e., hip arthroplasty) (Jones et al., 2007; Linsell et al., 2006). These limitations highlight an urgent need to investigate safe and scalable strategies to improve TKA outcomes.

Psychosocial processes have a clinically meaningful role in shaping TKA outcomes. Well-established presurgical cognitive and affective risk factors include pain catastrophizing (Lewis et al., 2015; M. Sullivan et al., 2011), kinesiophobia (Filardo et al., 2017), poor outcome expectations (M. Sullivan et al., 2011; Tilbury et al., 2018) and reward system dysfunction (Lewis et al., 2015). Meanwhile, emerging research suggests that positive, resilience-related factors such as positive affect, vitality, vigor, social support, self-efficacy, and global, trait-like resilience (Nwankwo et al., 2021) predict more favorable TKA outcomes (Cremeans-Smith et al., 2022; Edwards et al., 2022).

Major Gap in Knowledge

Despite known, modifiable psychological risk and resilience factors known to impact TKA outcomes, only recently have psychosocial processes in TKA been targeted in clinical trials. We are aware of a handful of investigations which have variously employed psychoeducation, guided imagery, motivational interviewing, and cognitive-behavioral approaches, which have demonstrated modest to poor efficacy in impacting postsurgical pain and function (Bay et al., 2018). Pain neuroscience education (PNE) is a relatively recent psychosocial intervention approach to chronic pain that educates patients on the modern neuroscientific understanding of mechanisms (e.g., central and peripheral sensitization), whose efficacy appears to be optimized when combined with an additional active treatment (e.g., physical therapy) informed by the patent's reconceptualization of pain (away from biomedical or biomechanical understanding and towards a modern neuroscientific understanding) achieved through PNE (Moseley & Butler, 2015; J. A. Watson et al., 2019). Initial studies on PNE alone in TKA patients show a favorable effect on patient satisfaction with the TKA procedure (Louw et al., 2019) and psychosocial risk factors including pain catastrophizing and kinesiophobia (Lluch et al., 2018) but no effect on pain or function.

How Proposed Work Will Fill the Gaps

The present study will address major gaps in knowledge by testing a novel prophylactic psychological intervention for TKA patients that targets reward system dysfunction, a central driver of chronic pain states. Specifically, we will test a novel Savoring Meditation (SM) intervention, which teaches patients how to augment positive affective functioning via meditating on a positive autobiographical memory. In addition, using a pain neuroscience education framework, SM will also educate participants on the neurophysiological basis for engaging in savoring meditation. Specifically, we will educate patients about the reward system in the brain, and how deficits in reward system functioning serve to maintain pain. Subsequently, we will explain to patients that savoring meditation has been empirically shown and is optimally suited to reduce pain vis-a-vis augmented reward system functioning. Patients randomized to SM will engage in 4 sessions of SM with a trained interventionist. They will be encouraged to use their SM skills in the postsurgical period to manage pain. We will compare the efficacy of SM to a Pain Self-Management and Education (PSME) condition, wherein patients will learn about biological, psychological, and social drivers of pain. The PSME condition will control for therapeutic alliance and treatment expectancies. We hypothesize that patients who undergo 4 sessions of SM will demonstrate reduced clinical pain and prescription opioid use across major assessment timepoints (post-treatment, 6-weeks, and 3-months), relative to PSME. Reward system function measured via self-report, affective pain modulation task performance, and electroencephalographic (EEG) based biomarkers will be investigated as a secondary outcome.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Optimizing Pain Self-Management in Total Knee Arthroplasty
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2026
Anticipated Study Completion Date :
Sep 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Savoring Meditation

A 4-session meditation intervention in which participants are trained to generate positive emotional states and focus their awareness on those states throughout the meditation.

Behavioral: Savoring Meditation
Participants will learn about pain neuroscience and will learn/practice a positive emotion generative practice (Savoring Meditation).

Other: Pain Self-Management and Education

Education Control

Behavioral: Pain Self-Management and Education
Participants will learn about the biopsychosocial drivers of chronic pain.

Outcome Measures

Primary Outcome Measures

  1. Clinical Pain [Baseline to 3 months post-surgery]

    Average pain intensity on numeric rating scale, aggregated across Ecological Momentary Assessment observations

  2. Opioid Use [Baseline to 3-months post-surgery]

    Morphine Equivalent Units per day, as assessed with Ecological Momentary Assessment

Secondary Outcome Measures

  1. Koos Jr [Baseline to 3 months post-surgery]

    Affective Pain Modulation Task Performance

  2. Positive Emotions [Baseline to 3-months post-surgery]

    PANAS-X

  3. Anhedonia [Baseline to 3-months post-surgery]

    SHAPS

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18-85 years old.

  • Have a physician-confirmed treatment plan to undergo unilateral TKA along with physician-confirmed knee osteoarthritis diagnosis.

  • Willingness and ability to comply with scheduled sessions and study procedures

Exclusion Criteria:
  • Member of a vulnerable population including pregnant women, children, prisoners, cognitively impaired, and non-English-speaking subjects.

  • Current unstable, severe medical comorbidity.

  • Current severe psychiatric comorbidity (e.g., schizophrenia, psychosis, or other unstable psychiatric disorder).

  • Current severe alcohol or substance use disorder.

  • Weekly or more frequent use of opioids in the past 30 days (other than tramadol and/or codeine) for therapeutic or non-therapeutic purposes.

  • Other surgery of the affected knee in the last 6 months.

  • Previous TKA.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Fontaine Research Park Charlottesville Virginia United States 22903

Sponsors and Collaborators

  • University of Virginia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Patrick Finan, PhD, Harold Carron Professor, University of Virginia
ClinicalTrials.gov Identifier:
NCT06038240
Other Study ID Numbers:
  • HSR230005
First Posted:
Sep 14, 2023
Last Update Posted:
Sep 14, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2023